$MOH
MOLINA HEALTHCARE, INC.

2019 Q2 Form 10-Q Financial Statement

#000117992919000134 Filed on July 31, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2018 Q2
Revenue $4.193B $4.883B
YoY Change -14.13% -2.32%
Cost Of Revenue $3.466B $3.968B
YoY Change -12.65% -14.02%
Gross Profit $583.0M $673.0M
YoY Change -13.37% 164.96%
Gross Profit Margin 13.9% 13.78%
Selling, General & Admin $438.0M $540.0M
YoY Change -18.89% 4.05%
% of Gross Profit 75.13% 80.24%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $22.00M $36.00M
YoY Change -38.89% -23.4%
% of Gross Profit 3.77% 5.35%
Operating Expenses $460.0M $565.0M
YoY Change -18.58% 1.62%
Operating Profit $265.0M $342.0M
YoY Change -22.51% -219.16%
Interest Expense $22.00M $32.00M
YoY Change -31.25% 18.52%
% of Operating Profit 8.3% 9.36%
Other Income/Expense, Net -$8.000M -$37.00M
YoY Change -78.38% 37.04%
Pretax Income $257.0M $305.0M
YoY Change -15.74% -197.13%
Income Tax $61.00M $103.0M
% Of Pretax Income 23.74% 33.77%
Net Earnings $196.0M $202.0M
YoY Change -2.97% -187.83%
Net Earnings / Revenue 4.67% 4.14%
Basic Earnings Per Share $3.15 $3.29
Diluted Earnings Per Share $3.06 $3.02
COMMON SHARES
Basic Shares Outstanding 62.10M shares 61.20M shares
Diluted Shares Outstanding 64.00M shares 66.70M shares

Balance Sheet

Concept 2019 Q2 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.323B $5.568B
YoY Change -22.36% 7.68%
Cash & Equivalents $2.253B $3.401B
Short-Term Investments $2.070B $2.176B
Other Short-Term Assets $301.0M $1.311B
YoY Change -77.04% 41.88%
Inventory
Prepaid Expenses
Receivables $1.239B $1.148B
Other Receivables $0.00 $0.00
Total Short-Term Assets $5.863B $8.027B
YoY Change -26.96% 11.97%
LONG-TERM ASSETS
Property, Plant & Equipment $373.0M $276.0M
YoY Change 35.14% -38.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $106.0M $28.00M
YoY Change 278.57% -40.43%
Total Long-Term Assets $827.0M $736.0M
YoY Change 12.36% -47.95%
TOTAL ASSETS
Total Short-Term Assets $5.863B $8.027B
Total Long-Term Assets $827.0M $736.0M
Total Assets $6.690B $8.763B
YoY Change -23.66% 2.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $337.0M $754.0M
YoY Change -55.31% 101.07%
Accrued Expenses $29.00M
YoY Change
Deferred Revenue $30.00M $193.0M
YoY Change -84.46%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $72.00M $484.0M
YoY Change -85.12% -37.39%
Total Short-Term Liabilities $3.388B $5.820B
YoY Change -41.79% 0.47%
LONG-TERM LIABILITIES
Long-Term Debt $1.241B $1.019B
YoY Change 21.79% 0.2%
Other Long-Term Liabilities $93.00M $68.00M
YoY Change 36.76% 25.93%
Total Long-Term Liabilities $1.334B $1.087B
YoY Change 22.72% 1.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.388B $5.820B
Total Long-Term Liabilities $1.334B $1.087B
Total Liabilities $4.954B $7.105B
YoY Change -30.27% 0.61%
SHAREHOLDERS EQUITY
Retained Earnings $1.491B $614.0M
YoY Change 142.83% -6.54%
Common Stock $240.0M $1.055B
YoY Change -77.25% 21.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.736B $1.658B
YoY Change
Total Liabilities & Shareholders Equity $6.690B $8.763B
YoY Change -23.66% 2.1%

Cashflow Statement

Concept 2019 Q2 2018 Q2
OPERATING ACTIVITIES
Net Income $196.0M $202.0M
YoY Change -2.97% -187.83%
Depreciation, Depletion And Amortization $22.00M $36.00M
YoY Change -38.89% -23.4%
Cash From Operating Activities -$93.00M -$80.00M
YoY Change 16.25% 70.21%
INVESTING ACTIVITIES
Capital Expenditures -$14.00M -$10.00M
YoY Change 40.0% -70.59%
Acquisitions
YoY Change
Other Investing Activities -$550.0M $263.0M
YoY Change -309.13% -155.72%
Cash From Investing Activities -$564.0M $253.0M
YoY Change -322.92% -150.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -314.0M -498.0M
YoY Change -36.95% -249.1%
NET CHANGE
Cash From Operating Activities -93.00M -80.00M
Cash From Investing Activities -564.0M 253.0M
Cash From Financing Activities -314.0M -498.0M
Net Change In Cash -971.0M -325.0M
YoY Change 198.77% 48.4%
FREE CASH FLOW
Cash From Operating Activities -$93.00M -$80.00M
Capital Expenditures -$14.00M -$10.00M
Free Cash Flow -$79.00M -$70.00M
YoY Change 12.86% 438.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Trading Symbol
TradingSymbol
MOH
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
us-gaap Premiums Earned Net
PremiumsEarnedNet
8001000000 USD
dei Entity Central Index Key
EntityCentralIndexKey
0001179929
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Address City Or Town
EntityAddressCityOrTown
Long Beach,
us-gaap Premiums Earned Net
PremiumsEarnedNet
8837000000 USD
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2019Q2 moh Health Care Organization Premium Tax Revenue
HealthCareOrganizationPremiumTaxRevenue
110000000 USD
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90802
dei City Area Code
CityAreaCode
562
CY2018Q2 moh Health Care Organization Premium Tax Revenue
HealthCareOrganizationPremiumTaxRevenue
106000000 USD
dei Local Phone Number
LocalPhoneNumber
435-3666
dei Security12b Title
Security12bTitle
Common Stock, $0.001 Par Value
moh Health Care Organization Premium Tax Revenue
HealthCareOrganizationPremiumTaxRevenue
248000000 USD
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62000000 shares
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
63000000 shares
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2019-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-31719
dei Entity Registrant Name
EntityRegistrantName
MOLINA HEALTHCARE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-4204626
dei Entity Address Address Line1
EntityAddressAddressLine1
200 Oceangate, Suite 100
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2019Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
62711000 shares
CY2019Q2 us-gaap Premiums Earned Net
PremiumsEarnedNet
4049000000 USD
moh Health Care Organization Premium Tax Revenue
HealthCareOrganizationPremiumTaxRevenue
210000000 USD
CY2019Q2 moh Health Care Organization Insurer Fee Revenue
HealthCareOrganizationInsurerFeeRevenue
0 USD
CY2018Q2 us-gaap Premiums Earned Net
PremiumsEarnedNet
4514000000 USD
moh Health Care Organization Insurer Fee Expense
HealthCareOrganizationInsurerFeeExpense
174000000 USD
CY2018Q2 moh Health Care Organization Insurer Fee Revenue
HealthCareOrganizationInsurerFeeRevenue
104000000 USD
CY2019Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
22000000 USD
CY2018Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
25000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
564000000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
47000000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
51000000 USD
CY2019Q2 us-gaap Interest Expense
InterestExpense
22000000 USD
CY2019Q2 us-gaap Restructuring Costs
RestructuringCosts
2000000 USD
CY2018Q2 us-gaap Restructuring Costs
RestructuringCosts
8000000 USD
us-gaap Restructuring Costs
RestructuringCosts
5000000 USD
moh Health Care Organization Insurer Fee Revenue
HealthCareOrganizationInsurerFeeRevenue
0 USD
moh Health Care Organization Insurer Fee Revenue
HealthCareOrganizationInsurerFeeRevenue
165000000 USD
CY2019Q2 us-gaap Insurance Services Revenue
InsuranceServicesRevenue
0 USD
CY2018Q2 us-gaap Insurance Services Revenue
InsuranceServicesRevenue
127000000 USD
us-gaap Insurance Services Revenue
InsuranceServicesRevenue
0 USD
us-gaap Insurance Services Revenue
InsuranceServicesRevenue
261000000 USD
CY2019Q2 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
34000000 USD
CY2018Q2 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
32000000 USD
us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
63000000 USD
us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
56000000 USD
CY2019Q2 us-gaap Revenues
Revenues
4193000000 USD
CY2018Q2 us-gaap Revenues
Revenues
4883000000 USD
us-gaap Revenues
Revenues
8312000000 USD
us-gaap Revenues
Revenues
9529000000 USD
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
328000000 USD
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
335000000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
630000000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
687000000 USD
CY2019Q2 moh Premium Tax Expenses
PremiumTaxExpenses
110000000 USD
CY2018Q2 moh Premium Tax Expenses
PremiumTaxExpenses
106000000 USD
moh Premium Tax Expenses
PremiumTaxExpenses
248000000 USD
moh Premium Tax Expenses
PremiumTaxExpenses
210000000 USD
CY2019Q2 moh Health Care Organization Insurer Fee Expense
HealthCareOrganizationInsurerFeeExpense
0 USD
CY2018Q2 moh Health Care Organization Insurer Fee Expense
HealthCareOrganizationInsurerFeeExpense
99000000 USD
moh Health Care Organization Insurer Fee Expense
HealthCareOrganizationInsurerFeeExpense
0 USD
us-gaap Restructuring Costs
RestructuringCosts
33000000 USD
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
3928000000 USD
CY2018Q2 us-gaap Costs And Expenses
CostsAndExpenses
4541000000 USD
us-gaap Costs And Expenses
CostsAndExpenses
7767000000 USD
us-gaap Costs And Expenses
CostsAndExpenses
8965000000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
265000000 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
342000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
545000000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
8000000 USD
CY2018Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1000000 USD
CY2018Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
1000000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-6000000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
17000000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
13000000 USD
CY2018Q2 us-gaap Interest Expense
InterestExpense
32000000 USD
us-gaap Interest Expense
InterestExpense
45000000 USD
us-gaap Interest Expense
InterestExpense
65000000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
14000000 USD
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17000000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15000000 USD
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8000000 USD
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-37000000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-28000000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-80000000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
257000000 USD
CY2018Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
305000000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
517000000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
484000000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
61000000 USD
CY2018Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
103000000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
123000000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
175000000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
196000000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
202000000 USD
us-gaap Net Income Loss
NetIncomeLoss
394000000 USD
us-gaap Net Income Loss
NetIncomeLoss
309000000 USD
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.15
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.10
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.06
CY2018Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
6.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.68
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
196000000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
202000000 USD
us-gaap Net Income Loss
NetIncomeLoss
394000000 USD
us-gaap Net Income Loss
NetIncomeLoss
309000000 USD
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
10000000 USD
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
2000000 USD
CY2018Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
4000000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-1000000 USD
CY2019Q2 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
1767000000 USD
CY2018Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
1961000000 USD
CY2019Q2 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
984000000 USD
CY2018Q4 us-gaap Assets
Assets
7154000000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-5000000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
204000000 USD
CY2018Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
203000000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
407000000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
304000000 USD
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2253000000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2826000000 USD
CY2019Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
2070000000 USD
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1681000000 USD
CY2019Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
1239000000 USD
CY2018Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
1330000000 USD
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
132000000 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
149000000 USD
CY2019Q2 us-gaap Derivative Assets Current
DerivativeAssetsCurrent
169000000 USD
CY2018Q4 us-gaap Derivative Assets Current
DerivativeAssetsCurrent
476000000 USD
CY2019Q2 us-gaap Assets Current
AssetsCurrent
5863000000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
6462000000 USD
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
373000000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
241000000 USD
CY2019Q2 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
180000000 USD
CY2018Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
190000000 USD
CY2019Q2 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
98000000 USD
CY2018Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
120000000 USD
CY2019Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
70000000 USD
CY2018Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
117000000 USD
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
106000000 USD
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
24000000 USD
CY2019Q2 us-gaap Assets
Assets
6690000000 USD
CY2018Q4 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
967000000 USD
CY2019Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
373000000 USD
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
390000000 USD
CY2019Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
30000000 USD
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
211000000 USD
CY2019Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
65000000 USD
CY2018Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
241000000 USD
CY2019Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
169000000 USD
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-8000000 USD
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6690000000 USD
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1491000000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1012000000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
1736000000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
1647000000 USD
CY2018Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
476000000 USD
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3388000000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4246000000 USD
CY2019Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1241000000 USD
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1020000000 USD
CY2019Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
232000000 USD
CY2018Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
197000000 USD
CY2019Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
93000000 USD
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
44000000 USD
CY2019Q2 us-gaap Liabilities
Liabilities
4954000000 USD
CY2018Q4 us-gaap Liabilities
Liabilities
5507000000 USD
CY2019Q2 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
0 USD
CY2018Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
0 USD
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
240000000 USD
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
643000000 USD
CY2019Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5000000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7154000000 USD
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1647000000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
198000000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-103000000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
5000000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3000000 USD
CY2019Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1835000000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
196000000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-321000000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
8000000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
18000000 USD
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1736000000 USD
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1337000000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
107000000 USD
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
108000000 USD
CY2018Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-6000000 USD
CY2018Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1000000 USD
CY2018Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1553000000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
20000000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14000000 USD
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
315000000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
202000000 USD
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-113000000 USD
CY2018Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1000000 USD
CY2018Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
15000000 USD
CY2018Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1658000000 USD
us-gaap Net Income Loss
NetIncomeLoss
394000000 USD
us-gaap Net Income Loss
NetIncomeLoss
309000000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
47000000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
73000000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-19000000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
6000000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
19000000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
13000000 USD
moh Amortization Of Debt Discount Premium And Sale Leaseback Financing Obligation
AmortizationOfDebtDiscountPremiumAndSaleLeasebackFinancingObligation
4000000 USD
moh Amortization Of Debt Discount Premium And Sale Leaseback Financing Obligation
AmortizationOfDebtDiscountPremiumAndSaleLeasebackFinancingObligation
13000000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
17000000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-15000000 USD
moh Noncash Restructuring Charges
NoncashRestructuringCharges
0 USD
moh Noncash Restructuring Charges
NoncashRestructuringCharges
17000000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
3000000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
4000000 USD
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-91000000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-18000000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
181000000 USD
us-gaap Increase Decrease In Health Care Insurance Liabilities
IncreaseDecreaseInHealthCareInsuranceLiabilities
-194000000 USD
us-gaap Increase Decrease In Health Care Insurance Liabilities
IncreaseDecreaseInHealthCareInsuranceLiabilities
-267000000 USD
moh Increase Decrease In Medical Premium Liability Due To Agency
IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency
17000000 USD
moh Increase Decrease In Medical Premium Liability Due To Agency
IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency
205000000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-61000000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
349000000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-181000000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-42000000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-3000000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
127000000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
156000000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
314000000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1162000000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
914000000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
791000000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1335000000 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
2000000 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
9000000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-393000000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
398000000 USD
us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
185000000 USD
us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
89000000 USD
moh Cash Paid For Settlement Of Conversion Option
CashPaidForSettlementOfConversionOption
473000000 USD
moh Cash Paid For Settlement Of Conversion Option
CashPaidForSettlementOfConversionOption
134000000 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
473000000 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
134000000 USD
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
424000000 USD
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
113000000 USD
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
220000000 USD
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
0 USD
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0 USD
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
300000000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
27000000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-1000000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-362000000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-503000000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-599000000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
209000000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2926000000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3290000000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2327000000 USD
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3499000000 USD
us-gaap Stock Issued1
StockIssued1
7000000 USD
us-gaap Stock Issued1
StockIssued1
6000000 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 USD
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 USD
us-gaap Notes Issued1
NotesIssued1
0 USD
us-gaap Notes Issued1
NotesIssued1
131000000 USD
moh Notes Issued Fair Value Adjustment Increase Decrease
NotesIssuedFairValueAdjustmentIncreaseDecrease
0 USD
moh Notes Issued Fair Value Adjustment Increase Decrease
NotesIssuedFairValueAdjustmentIncreaseDecrease
-23000000 USD
us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
0 USD
us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
108000000 USD
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 Segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The preparation of consolidated financial statements in conformity with generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Principal areas requiring the use of estimates include:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The determination of medical claims and benefits payable of our Health Plans segment;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Health plans’ contractual provisions that may limit revenue recognition based upon the costs incurred or the profits realized under a specific contract;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Health plans’ quality incentives that allow us to recognize incremental revenue if certain quality standards are met;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Settlements under risk or savings sharing programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The assessment of long-lived and intangible assets, and goodwill for impairment;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The determination of reserves for potential absorption of claims unpaid by insolvent providers;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The determination of reserves for litigation outcomes;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The determination of valuation allowances for deferred tax assets; and</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Arial;font-size:10pt;">•</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The determination of unrecognized tax benefits. </span></div>
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2253000000 USD
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3401000000 USD
CY2019Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
74000000 USD
CY2018Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
98000000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2327000000 USD
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3499000000 USD
CY2019Q2 moh Amounts Dueto Government Agencies Medical Cost Floorsand Corridors
AmountsDuetoGovernmentAgenciesMedicalCostFloorsandCorridors
93000000 USD
CY2018Q4 moh Amounts Dueto Government Agencies Medical Cost Floorsand Corridors
AmountsDuetoGovernmentAgenciesMedicalCostFloorsandCorridors
103000000 USD
CY2019Q2 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable
-625000000 USD
CY2019Q2 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Receivable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable
71000000 USD
CY2019Q2 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Net Payable Receivable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivable
-554000000 USD
CY2019Q2 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Net Payable Receivable Prior Years
AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears
390000000 USD
CY2018Q4 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Payable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable
-466000000 USD
CY2018Q4 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Receivable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable
34000000 USD
CY2018Q4 moh Affordable Care Act Premium Stabilization Program Risk Adjustment Net Payable Receivable
AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivable
-432000000 USD
CY2019Q2 moh Amounts Dueto Government Agencies Medical Cost Floorsand Corridors
AmountsDuetoGovernmentAgenciesMedicalCostFloorsandCorridors
93000000 USD
CY2018Q4 moh Amounts Dueto Government Agencies Medical Cost Floorsand Corridors
AmountsDuetoGovernmentAgenciesMedicalCostFloorsandCorridors
103000000 USD
CY2019Q2 moh Amounts Dueto Government Agencies Amounts Due State
AmountsDuetoGovernmentAgenciesAmountsDueState
93000000 USD
CY2018Q4 moh Amounts Dueto Government Agencies Amounts Due State
AmountsDuetoGovernmentAgenciesAmountsDueState
81000000 USD
CY2019Q2 moh Amounts Dueto Government Agencies Risk Adjustment
AmountsDuetoGovernmentAgenciesRiskAdjustment
625000000 USD
CY2018Q4 moh Amounts Dueto Government Agencies Risk Adjustment
AmountsDuetoGovernmentAgenciesRiskAdjustment
466000000 USD
CY2019Q2 moh Amounts Dueto Government Agencies Cost Sharing Reduction
AmountsDuetoGovernmentAgenciesCostSharingReduction
0 USD
CY2018Q4 moh Amounts Dueto Government Agencies Cost Sharing Reduction
AmountsDuetoGovernmentAgenciesCostSharingReduction
183000000 USD
CY2019Q2 moh Amounts Dueto Government Agencies Other
AmountsDuetoGovernmentAgenciesOther
173000000 USD
CY2018Q4 moh Amounts Dueto Government Agencies Other
AmountsDuetoGovernmentAgenciesOther
134000000 USD
CY2019Q2 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
984000000 USD
CY2018Q4 moh Medical Premium Liability Due To Agency
MedicalPremiumLiabilityDueToAgency
967000000 USD
CY2019Q2 moh Maximum Available Quality Incentive Premium Current Year
MaximumAvailableQualityIncentivePremiumCurrentYear
46000000 USD
CY2018Q2 moh Maximum Available Quality Incentive Premium Current Year
MaximumAvailableQualityIncentivePremiumCurrentYear
47000000 USD
moh Maximum Available Quality Incentive Premium Current Year
MaximumAvailableQualityIncentivePremiumCurrentYear
91000000 USD
moh Maximum Available Quality Incentive Premium Current Year
MaximumAvailableQualityIncentivePremiumCurrentYear
87000000 USD
CY2019Q2 moh Amount Of Current Year Quality Incentive Premium Revenue Recognized
AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized
37000000 USD
CY2018Q2 moh Amount Of Current Year Quality Incentive Premium Revenue Recognized
AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized
34000000 USD
moh Amount Of Current Year Quality Incentive Premium Revenue Recognized
AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized
63000000 USD
moh Amount Of Current Year Quality Incentive Premium Revenue Recognized
AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized
58000000 USD
CY2019Q2 moh Amount Of Quality Incentive Premium Revenue Recognized From Prior Year
AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear
10000000 USD
CY2018Q2 moh Amount Of Quality Incentive Premium Revenue Recognized From Prior Year
AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear
12000000 USD
moh Amount Of Quality Incentive Premium Revenue Recognized From Prior Year
AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear
30000000 USD
moh Amount Of Quality Incentive Premium Revenue Recognized From Prior Year
AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear
23000000 USD
CY2019Q2 moh Quality Incentive Premium Revenue Recognized
QualityIncentivePremiumRevenueRecognized
47000000 USD
CY2018Q2 moh Quality Incentive Premium Revenue Recognized
QualityIncentivePremiumRevenueRecognized
46000000 USD
moh Quality Incentive Premium Revenue Recognized
QualityIncentivePremiumRevenueRecognized
93000000 USD
moh Quality Incentive Premium Revenue Recognized
QualityIncentivePremiumRevenueRecognized
81000000 USD
CY2019Q2 moh Quality Incentive Premium Revenue As A Percentage Of Total Revenue
QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue
0.012
CY2018Q2 moh Quality Incentive Premium Revenue As A Percentage Of Total Revenue
QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue
0.010
moh Quality Incentive Premium Revenue As A Percentage Of Total Revenue
QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue
0.012
moh Quality Incentive Premium Revenue As A Percentage Of Total Revenue
QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue
0.009
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with a maximum maturity of </span><span style="font-family:Arial;font-size:10pt;"><span>10 years</span></span><span style="font-family:Arial;font-size:10pt;">, or </span><span style="font-family:Arial;font-size:10pt;"><span>10 years</span></span><span style="font-family:Arial;font-size:10pt;"> average life for structured securities. Restricted investments are invested principally in certificates of deposit and U.S. Treasury securities. Concentration of credit risk with respect to </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">accounts receivable is generally limited because our payors consist principally of the federal government, and governments of each state or commonwealth in which our health plan subsidiaries operate. </span></div>
moh Investments Maturity Period
InvestmentsMaturityPeriod
P10Y
moh Investments Maturity Period
InvestmentsMaturityPeriod
P10Y
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
500000 shares
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
196000000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
202000000 USD
us-gaap Net Income Loss
NetIncomeLoss
394000000 USD
us-gaap Net Income Loss
NetIncomeLoss
309000000 USD
CY2019Q1 us-gaap Shares Outstanding
SharesOutstanding
62100000 shares
CY2018Q1 us-gaap Shares Outstanding
SharesOutstanding
61200000 shares
CY2018Q4 us-gaap Shares Outstanding
SharesOutstanding
62100000 shares
CY2017Q4 us-gaap Shares Outstanding
SharesOutstanding
59300000 shares
CY2019Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
0 shares
CY2018Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
0 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
0 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
1100000 shares
CY2019Q2 moh Weighted Average Numberof Shares Share Based Compensation
WeightedAverageNumberofSharesShareBasedCompensation
0 shares
CY2018Q2 moh Weighted Average Numberof Shares Share Based Compensation
WeightedAverageNumberofSharesShareBasedCompensation
0 shares
moh Weighted Average Numberof Shares Share Based Compensation
WeightedAverageNumberofSharesShareBasedCompensation
0 shares
moh Weighted Average Numberof Shares Share Based Compensation
WeightedAverageNumberofSharesShareBasedCompensation
100000 shares
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62100000 shares
CY2018Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61200000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62100000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60500000 shares
CY2019Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1300000 shares
CY2018Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
4900000 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
2400000 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
4800000 shares
CY2019Q2 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
CY2018Q2 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
400000 shares
CY2019Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
600000 shares
CY2018Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
200000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
600000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
200000 shares
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64000000.0 shares
CY2018Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66700000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65100000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66000000.0 shares
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.15
CY2018Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.34
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.10
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.06
CY2018Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
6.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.68
CY2019Q2 moh Antidilutive Securities Excludedfrom Computationof Eps Share Based Compensation Amount
AntidilutiveSecuritiesExcludedfromComputationofEPSShareBasedCompensationAmount
0 shares
CY2018Q2 moh Antidilutive Securities Excludedfrom Computationof Eps Share Based Compensation Amount
AntidilutiveSecuritiesExcludedfromComputationofEPSShareBasedCompensationAmount
400000 shares
moh Antidilutive Securities Excludedfrom Computationof Eps Share Based Compensation Amount
AntidilutiveSecuritiesExcludedfromComputationofEPSShareBasedCompensationAmount
0 shares
moh Antidilutive Securities Excludedfrom Computationof Eps Share Based Compensation Amount
AntidilutiveSecuritiesExcludedfromComputationofEPSShareBasedCompensationAmount
400000 shares
CY2019Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
2239000000 USD
CY2019Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
169000000 USD
CY2018Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
2157000000 USD
CY2018Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
476000000 USD
CY2019Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
2064000000 USD
CY2019Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
8000000 USD
CY2019Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000000 USD
CY2019Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
2070000000 USD
CY2019Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
821000000 USD
CY2019Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
821000000 USD
CY2019Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
917000000 USD
CY2019Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
921000000 USD
CY2019Q2 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
124000000 USD
CY2019Q2 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
125000000 USD
CY2019Q2 us-gaap Available For Sale Securities Debt Maturities After Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
202000000 USD
CY2019Q2 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
203000000 USD
CY2019Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
2064000000 USD
CY2019Q2 us-gaap Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue
2070000000 USD
CY2019Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
0 USD
CY2019Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
0 USD
CY2019Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
0 Security
CY2019Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
377000000 USD
CY2019Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
2000000 USD
CY2019Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
235 Security
CY2018Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
509000000 USD
CY2018Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
3000000 USD
CY2018Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
285 Security
CY2018Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
694000000 USD
CY2018Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
8000000 USD
CY2018Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
516 Security
CY2019Q2 us-gaap Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount
92000000 USD
CY2019Q2 us-gaap Held To Maturity Securities Debt Maturities Within One Year Fair Value
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
92000000 USD
CY2019Q2 us-gaap Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
6000000 USD
CY2019Q2 us-gaap Held To Maturity Securities Debt Maturities After One Through Five Years Fair Value
HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
6000000 USD
CY2019Q2 us-gaap Held To Maturity Securities Debt Maturities Single Maturity Date Amortized Cost Basis
HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
98000000 USD
CY2019Q2 us-gaap Held To Maturity Securities Debt Maturities Single Maturity Date Fair Value
HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateFairValue
98000000 USD
us-gaap Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense
ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">The following table provides the details of our medical claims and benefits payable as of the dates indicated.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">June 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,<br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Fee-for-service claims incurred but not paid (“IBNP”)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,346</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,562</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Pharmacy payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>117</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>115</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Capitation payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>241</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>232</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,767</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><span>1,961</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:10pt;"><br/></span></div>
CY2019Q2 moh Liabilityfor Unpaid Claimsand Claims Adjustment Expense Incurredbut Not Paid Ibnp Feeforservice Claims Amount
LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount
1346000000 USD
CY2018Q4 moh Liabilityfor Unpaid Claimsand Claims Adjustment Expense Incurredbut Not Paid Ibnp Feeforservice Claims Amount
LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount
1562000000 USD
CY2019Q2 moh Pharmacy Claims Payable
PharmacyClaimsPayable
117000000 USD
CY2018Q4 moh Pharmacy Claims Payable
PharmacyClaimsPayable
115000000 USD
CY2019Q2 moh Capitation Claims Payable
CapitationClaimsPayable
63000000 USD
CY2018Q4 moh Capitation Claims Payable
CapitationClaimsPayable
52000000 USD
CY2019Q2 moh Other Claims Payable
OtherClaimsPayable
241000000 USD
CY2018Q4 moh Other Claims Payable
OtherClaimsPayable
232000000 USD
CY2019Q2 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
1767000000 USD
CY2018Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
1961000000 USD
CY2019Q2 moh Medical Claims And Benefits Payable
MedicalClaimsAndBenefitsPayable
112000000 USD
CY2018Q4 moh Medical Claims And Benefits Payable
MedicalClaimsAndBenefitsPayable
107000000 USD
CY2018Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
1961000000 USD
CY2017Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
2192000000 USD
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
7069000000 USD
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
7870000000 USD
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-232000000 USD
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-298000000 USD
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
6837000000 USD
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
7572000000 USD
moh Medical Claims And Benefits Payable Adjustments Change In Provider
MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
4000000 USD
moh Medical Claims And Benefits Payable Adjustments Change In Provider
MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
56000000 USD
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
5585000000 USD
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
6248000000 USD
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
1450000000 USD
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
1652000000 USD
us-gaap Payments For Losses And Loss Adjustment Expense
PaymentsForLossesAndLossAdjustmentExpense
7035000000 USD
us-gaap Payments For Losses And Loss Adjustment Expense
PaymentsForLossesAndLossAdjustmentExpense
7900000000 USD
CY2019Q2 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
1767000000 USD
CY2018Q2 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
1920000000 USD
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-232000000 USD
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-298000000 USD
CY2019Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1317000000 USD
CY2019Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
73000000 USD
CY2019Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
16000000 USD
CY2019Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
722000000 USD
CY2019Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
22000000 USD
CY2019Q2 moh Longterm Debt Maturities Repaymentsof Principalin Year Six
LongtermDebtMaturitiesRepaymentsofPrincipalinYearSix
154000000 USD
CY2019Q2 moh Longterm Debt Maturities Repaymentsof Principalafter Year Six
LongtermDebtMaturitiesRepaymentsofPrincipalafterYearSix
330000000 USD
CY2019Q2 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
0 USD
CY2018Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
1000000 USD
CY2019Q2 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
0 USD
CY2018Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
1000000 USD
CY2019Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
65000000 USD
CY2018Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
241000000 USD
CY2019Q2 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
9000000 USD
CY2018Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
10000000 USD
CY2019Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1241000000 USD
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1020000000 USD
CY2019Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
0 USD
CY2018Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
2000000 USD
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1000000 USD
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
4000000 USD
CY2019Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1000000 USD
CY2018Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
6000000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
4000000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
13000000 USD
CY2019Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
1000000 USD
CY2018Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
8000000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
5000000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
17000000 USD
CY2019Q2 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
37000000 USD
CY2019Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
12000000 USD
CY2013 us-gaap Debt Conversion Converted Instrument Warrants Or Options Issued1
DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
13500000 shares
CY2013Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
53.8475
CY2019Q2 us-gaap Share Based Compensation
ShareBasedCompensation
10000000 USD
CY2018Q2 us-gaap Share Based Compensation
ShareBasedCompensation
7000000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
19000000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
13000000 USD
CY2019Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
62000000 USD
moh Unrecognized Compensation Forfeited Rate
UnrecognizedCompensationForfeitedRate
0.152
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
604310 shares
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
71.50
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
357239 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
137.42
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
143186 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
70.57
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
34607 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
83.05
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
783756 shares
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
101.20
moh Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue
49000000 USD
moh Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue
41000000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
20000000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
17000000 USD
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 Segment
CY2019Q2 us-gaap Revenues
Revenues
4193000000 USD
CY2018Q2 us-gaap Revenues
Revenues
4883000000 USD
us-gaap Revenues
Revenues
8312000000 USD
us-gaap Revenues
Revenues
9529000000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
265000000 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
342000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
545000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
564000000 USD
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8000000 USD
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-37000000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-28000000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-80000000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
257000000 USD
CY2018Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
305000000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
517000000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
484000000 USD
CY2019Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P10Y
CY2019Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P10Y
CY2019Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y
CY2019Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
232000000 USD
CY2019Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
239000000 USD
CY2019Q2 us-gaap Lessee Finance Lease Renewal Term1
LesseeFinanceLeaseRenewalTerm1
P25Y
CY2019Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P17Y
CY2019Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.055
CY2019Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.066
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
8000000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
17000000 USD
CY2019Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
4000000 USD
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
8000000 USD
CY2019Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
4000000 USD
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
8000000 USD
CY2019Q2 moh Finance Lease Cost
FinanceLeaseCost
8000000 USD
moh Finance Lease Cost
FinanceLeaseCost
16000000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
19000000 USD
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
7000000 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
3000000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
95000000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
241000000 USD
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
77000000 USD
CY2019Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
29000000 USD
CY2019Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
56000000 USD
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
85000000 USD
CY2019Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
233000000 USD
CY2019Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
7000000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
18000000 USD
CY2019Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
11000000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
28000000 USD
CY2019Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
22000000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
18000000 USD
CY2019Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
22000000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
12000000 USD
CY2019Q2 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
21000000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
10000000 USD
CY2019Q2 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
21000000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
9000000 USD
CY2019Q2 us-gaap Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
311000000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
95000000 USD
CY2019Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
408000000 USD
CY2019Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10000000 USD
CY2019Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
169000000 USD
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
85000000 USD
CY2019Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
239000000 USD

Files In Submission

Name View Source Status
0001179929-19-000134-index-headers.html Edgar Link pending
0001179929-19-000134-index.html Edgar Link pending
0001179929-19-000134.txt Edgar Link pending
0001179929-19-000134-xbrl.zip Edgar Link pending
a2019equityincentiveplan.htm Edgar Link pending
a2019equityincentiveplan001.jpg Edgar Link pending
a2019equityincentiveplan002.jpg Edgar Link pending
a2019equityincentiveplan003.jpg Edgar Link pending
a2019equityincentiveplan004.jpg Edgar Link pending
a2019equityincentiveplan005.jpg Edgar Link pending
a2019equityincentiveplan006.jpg Edgar Link pending
a2019equityincentiveplan007.jpg Edgar Link pending
ex101_2019-rsa.htm Edgar Link pending
ex101_2019-rsa001.jpg Edgar Link pending
ex101_2019-rsa002.jpg Edgar Link pending
ex101_2019-rsa003.jpg Edgar Link pending
ex101_2019-rsa004.jpg Edgar Link pending
ex101_2019-rsa005.jpg Edgar Link pending
ex101_2019-rsa006.jpg Edgar Link pending
ex103_2019eip-rsa.htm Edgar Link pending
ex103_2019eip-rsa001.jpg Edgar Link pending
ex103_2019eip-rsa002.jpg Edgar Link pending
ex103_2019eip-rsa003.jpg Edgar Link pending
ex103_2019eip-rsa004.jpg Edgar Link pending
ex103_2019eip-rsa005.jpg Edgar Link pending
ex103_2019eip-rsa006.jpg Edgar Link pending
ex104_2019eip-psu.htm Edgar Link pending
ex104_2019eip-psu001.jpg Edgar Link pending
ex104_2019eip-psu002.jpg Edgar Link pending
ex104_2019eip-psu003.jpg Edgar Link pending
ex104_2019eip-psu004.jpg Edgar Link pending
ex104_2019eip-psu005.jpg Edgar Link pending
ex104_2019eip-psu006.jpg Edgar Link pending
ex104_2019eip-psu007.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
moh-06302019x10q.htm Edgar Link pending
moh-06302019x10q_htm.xml Edgar Link completed
moh-06302019xex311.htm Edgar Link pending
moh-06302019xex312.htm Edgar Link pending
moh-06302019xex321.htm Edgar Link pending
moh-06302019xex322.htm Edgar Link pending
moh-20190630.xsd Edgar Link pending
moh-20190630_cal.xml Edgar Link unprocessable
moh-20190630_def.xml Edgar Link unprocessable
moh-20190630_lab.xml Edgar Link unprocessable
moh-20190630_pre.xml Edgar Link unprocessable
molinalogo2016a26.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending